Literature DB >> 9295373

Conduction in segmentally demyelinated mammalian central axons.

P A Felts1, T A Baker, K J Smith.   

Abstract

The prominent symptoms associated with central demyelinating diseases such as multiple sclerosis (MS) are primarily caused by conduction deficits in affected axons. The symptoms may go into remission, but the mechanisms underlying remissions are uncertain. One factor that could be important is the restoration of conduction to affected axons, but it is not known whether demyelinated central axons resemble their peripheral counterparts in being able to conduct in the absence of repair by remyelination. In the present study we have made intra-axonal recordings from central axons affected by a demyelinating lesion, and then the axons have been labeled ionophoretically to permit their subsequent identification. Ultrastructural examination of 23 labeled preparations has established that some segmentally demyelinated central axons can conduct, and that they can do so over continuous lengths of demyelination exceeding several internodes (2500 micron). Such segmentally demyelinated central axons were found to conduct with the anticipated reduction in velocity and a refractory period of transmission (RPT) as much as 34 times the value obtained from the nondemyelinated portion of the same axon; the RPT was typically prolonged to 2-5 times the normal value. We conclude that some segmentally demyelinated central axons can conduct, and we propose that the restoration of conduction to such axons is likely to contribute to the remissions commonly observed in diseases such as MS.

Entities:  

Mesh:

Year:  1997        PMID: 9295373      PMCID: PMC6573430     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  48 in total

1.  The pathophysiology of myelin basic protein-induced acute experimental allergic encephalomyelitis in the Lewis rat.

Authors:  M P Pender
Journal:  J Neurol Sci       Date:  1988-09       Impact factor: 3.181

2.  Effect of demyelination on conduction in the central nervous system.

Authors:  W I McDonald; T A Sears
Journal:  Nature       Date:  1969-01-11       Impact factor: 49.962

3.  Restoration of normal conduction properties in demyelinated spinal cord axons in the adult rat by transplantation of exogenous Schwann cells.

Authors:  O Honmou; P A Felts; S G Waxman; J D Kocsis
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

Review 4.  Rachelle Fishman-Matthew Moore Lecture. The pathological and clinical dynamics of multiple sclerosis.

Authors:  W I McDonald
Journal:  J Neuropathol Exp Neurol       Date:  1994-07       Impact factor: 3.685

5.  A computer simulation of conduction in demyelinated nerve fibres.

Authors:  Z J Koles; M Rasminsky
Journal:  J Physiol       Date:  1972-12       Impact factor: 5.182

6.  The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination.

Authors:  H Bostock; T A Sears
Journal:  J Physiol       Date:  1978-07       Impact factor: 5.182

7.  Ethidium bromide induced demyelination in the spinal cord of the cat.

Authors:  W F Blakemore
Journal:  Neuropathol Appl Neurobiol       Date:  1982 Sep-Oct       Impact factor: 8.090

8.  Central axons in injured cat spinal cord recover electrophysiological function following remyelination by Schwann cells.

Authors:  A R Blight; W Young
Journal:  J Neurol Sci       Date:  1989-06       Impact factor: 3.181

9.  Saltatory conduction precedes remyelination in axons demyelinated with lysophosphatidyl choline.

Authors:  K J Smith; H Bostock; S M Hall
Journal:  J Neurol Sci       Date:  1982-04       Impact factor: 3.181

10.  Demyelination and remyelination in the rat central nervous system following ethidium bromide injection.

Authors:  K Yajima; K Suzuki
Journal:  Lab Invest       Date:  1979-11       Impact factor: 5.662

View more
  55 in total

1.  Ion channel sequestration in central nervous system axons.

Authors:  M N Rasband; P Shrager
Journal:  J Physiol       Date:  2000-05-15       Impact factor: 5.182

2.  Voluntary contraction impairs the refractory period of transmission in healthy human axons.

Authors:  S Kuwabara; C S Lin; I Mogyoros; C Cappelen-Smith; D Burke
Journal:  J Physiol       Date:  2001-02-15       Impact factor: 5.182

3.  Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample.

Authors:  Po H Lu; Grace J Lee; Erika P Raven; Kathleen Tingus; Theresa Khoo; Paul M Thompson; George Bartzokis
Journal:  J Clin Exp Neuropsychol       Date:  2011-08-26       Impact factor: 2.475

4.  Age-related molecular reorganization at the node of Ranvier.

Authors:  Jason D Hinman; Alan Peters; Howard Cabral; Douglas L Rosene; William Hollander; Matthew N Rasband; Carmela R Abraham
Journal:  J Comp Neurol       Date:  2006-04-01       Impact factor: 3.215

5.  New developments in the treatment of optic neuritis.

Authors:  Thomas M Jenkins; Ahmed T Toosy
Journal:  Eye Brain       Date:  2010-06-17

Review 6.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

7.  BRAIN MYELINATION IN PREVALENT NEUROPSYCHIATRIC DEVELOPMENTAL DISORDERS: PRIMARY AND COMORBID ADDICTION.

Authors:  George Bartzokis
Journal:  Adolesc Psychiatry       Date:  2005

8.  Postmortem brain MRI is related to cognitive decline, independent of cerebral vessel disease in older adults.

Authors:  Robert J Dawe; Lei Yu; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Patricia A Boyle
Journal:  Neurobiol Aging       Date:  2018-05-23       Impact factor: 4.673

9.  The effects of normal aging on myelinated nerve fibers in monkey central nervous system.

Authors:  Alan Peters
Journal:  Front Neuroanat       Date:  2009-07-06       Impact factor: 3.856

Review 10.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.